Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer Article

Industry Collaboration International Collaboration

cited authors

  • Evans, T. R. J.; Van Cutsem, E.; Moore, M. J.; Bazin, I. S.; Rosemurgy, A.; Bodoky, G.; Deplanque, G.; Harrison, M.; Melichar, B.; Pezet, D.; Elekes, A.; Rock, E.; Lin, C.; Strauss, L.; O'Dwyer, P. J.

Publication Date

  • February 1, 2017

webpage

published in

category

keywords

  • anticancer therapy
  • dasatinib
  • gemcitabine
  • pancreatic cancer

start page

  • 354

end page

  • 361

volume

  • 28

issue

  • 2